Lantheus Holdings, Inc. — fact timeline

Lantheus Holdings, Inc. updated its the three months ended March 31, 2026 guidance (reaffirmed).

“On May 7, 2026, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three months ended March 31, 2026. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference.”

Lantheus Holdings, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP at the 2026-04-30 meeting.

“Proposal 6 – Ratification of Appointment of Deloitte & Touche LLP The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s shareholders based on the following vote: Votes For Votes Against Abstentions Broker Non-Votes 60,157,609 221,161.72 27,979.73 0”

Lantheus Holdings, Inc. shareholders approved Approval of the A&R 2026 Equity Incentive Plan at the 2026-04-30 meeting.

“Proposal 5 – Approval of the A&R 2026 Equity Incentive Plan The A&R 2026 Equity Incentive Plan was approved by the Company’s shareholders based on the following vote: Votes For Votes Against Abstentions Broker Non-Votes 54,021,539 1,973,725.72 62,703.73 4,348,782”

Lantheus Holdings, Inc. shareholders approved Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to declassify its Board of Directors at the 2026-04-30 meeting.

“Proposal 4 – Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to declassify its Board of Directors The amendment to the Company’s Amended and Restated Certificate of Incorporation to declassify its Board of Directors was approved by the Company’s shareholders based on the following vote: Votes For Votes Against Abstentions Broker Non-Votes 55,995,083.73 28,070 34,814.73 4,348,782”

Lantheus Holdings, Inc. shareholders approved Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation paid to the Company’s named executive officers at the 2026-04-30 meeting.

“Proposal 3 – Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation paid to the Company’s named executive officers The approval, on an advisory basis, of the frequency of future “say on pay” votes was approved by the Company’s shareholders based on the following vote: One Year Two Years Three Years Abstentions Broker Non-Votes 54,764,000.73 13,872 1,236,685 43,410.73 4,348,782”

Lantheus Holdings, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers at the 2026-04-30 meeting.

“Proposal 2 – Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers The approval, on an advisory basis, of the compensation paid to the Company’s named executive officers was approved by the Company’s shareholders based on the following vote: Votes For Votes Against Abstentions Broker Non-Votes 54,068,553 1,936,861.72 52,553.73 4,348,782”

Lantheus Holdings, Inc. shareholders approved Election of Directors at the 2026-04-30 meeting.

“Proposal 1 – Election of Directors Each of the following nominees for Class II director was elected by the Company’s shareholders to serve a three-year term expiring at the 2029 Annual Meeting of Shareholders based on the following vote: Nominee Votes For Votes Against Abstentions Broker Non-Votes Minnie Baylor-Henry 55,652,541 364,914.72 40,512.73 4,348,782 Heinz Mäusli 55,641,028 370,740.72 46,199.73 4,348,782 Julie McHugh 54,136,150 1,876,383.72 45,434.73 4,348,782 Dr. Phuong Khanh (P.K.) Morrow 55,815,438 215,057.72 27,472.73 4,348,782”

Lantheus Holdings, Inc.: Amended certificate of incorporation to declassify the Board of Directors over a three-year period and allow shareholder removal of directors with or without cause (effective 2026-04-30).

“On April 30, 2026, the Company filed a Certificate of Amendment (the “ Certificate of Amendment ”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware effecting an amendment to declassify the Company’s Board of Directors over a three-year period.”

Lantheus Holdings, Inc. completed an acquisition involving Life Medical Group Limited for $350 million (closed 2025-07-21).

“the Transaction pursuant to the Agreement. In accordance with the Agreement, upon the closing of the Transaction, the Purchaser paid the Seller an upfront cash payment of $350 million (following applicable purchase price adjustments under the Agreement) in exchange for all of the outstanding share capital of Life Molecular. The foregoing description of the”

Lantheus Holdings, Inc.: Amended and restated Bylaws effective May 1, 2025, adding procedural and disclosure requirements for special meetings, updating meeting rules, revising director nomination and proxy access procedures, providing automatic director reduction on vacancies, and making ministerial changes (effective 2025-05-01).

“On May 1, 2025, the Board of Directors of Lantheus Holdings, Inc. (the “ Company ”) amended and restated the Company’s Bylaws (as so amended and restated, the “ Amended and Restated Bylaws ”), effective immediately. Among other things, the amendments effected by the Amended and Restated Bylaws (i) add procedural and disclosure requirements for stockholders calling special meetings of stockholders, (ii) update procedures and rules relating to stockholder meetings, (iii) revise procedural mechanics and disclosure requirements applicable to stockholder nominations of directors, submissions of proposals regarding other business at stockholder meetings, proxy access and general director eligibility, (iv) provide that the authorized number of directors is automatically reduced upon any vacancy on the Board of Directors of the Company to eliminate such vacancy, (v) make certain changes to conform to recent amendments to the Delaware General Corporation Law and (vi) make certain other minister”

Lantheus Holdings, Inc. completed an acquisition involving Evergreen Theragnostics, Inc. for approximately $275 million in cash (closed 2025-04-01).

“(CDMO) services as well as drug discovery and commercialization of proprietary products. In connection with the closing of the Merger, Lantheus Medical paid approximately $275 million in cash, subject to customary adjustments as set forth in the Merger Agreement, representing the $250 million upfront cash payment and a $25 million milestone payment in respect”

Phuong Khanh Morrow was appointed as Director at Lantheus Holdings, Inc..

“On January 29, 2025, the board of directors of Lantheus Holdings, Inc. (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Phuong Khanh (P.K.) Morrow, M.D., an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology, to the Board.”

Julie Eastland was appointed as Director at Lantheus Holdings, Inc..

“On September 3, 2024, the board of directors of Lantheus Holdings, Inc. (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Julie Eastland, an experienced biotechnology and financial executive, to the Board.”

Andrea Sabens changed role as Chief Accounting Officer at Lantheus Holdings, Inc..

“Andrea Sabens, the Company’s current Chief Accounting Officer and principal accounting officer, will transition to a new role at the Company and will no longer serve as the principal accounting officer as of the Effective Date.”

Kimberly Brown was appointed as Chief Accounting Officer at Lantheus Holdings, Inc..

“On June 17, 2024, Kimberly Brown was appointed as the Chief Accounting Officer of Lantheus Holdings, Inc. (the “Company”) and its subsidiaries, effective July 1, 2024.”

Jean-Claude Provost was appointed as Chief Science Officer at Lantheus Holdings, Inc..

“On May 15, 2024, Lantheus Holdings, Inc. (the “Company”) announced that, upon the effectiveness of his appointment as Chief Science Officer of the Company on May 28, 2024, Jean-Claude Provost MD will no longer serve as the Company’s Chief Medical Officer.”

Lantheus Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $370.0 million, net income $131.1 million, EPS $1.87. Guidance raised.

“Lantheus Reports First Quarter 2024 Financial Results First Quarter 2024 • Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 • GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per share of $0.04 in first quarter 2023. Adjusted fully diluted net income per share of $1.69 compared to adjusted fully diluted net income per share of $1.47 in the first quarter 2023 • The Company increases full year 2024 net revenue and earnings guidance and provides guidance for the second quarter 2024”

Lantheus Holdings, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP at the 2024-04-25 meeting.

“The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified by the Company’s stockholders based on the following vote: Votes For Votes Against Abstentions Broker Non-Votes 62,428,177.56 521,644.00 87,441.00 0”

Lantheus Holdings, Inc. shareholders approved Approval of an amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 4,000,000 shares at the 2024-04-25 meeting.

“The approval of an amendment to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 4,000,000 shares was approved by the Company’s stockholders based on the following vote: Votes For Votes Against Abstentions Broker Non-Votes 54,662,118.66 3,335,696.04 109,627.00 4,929,820.86”

Lantheus Holdings, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to our named executive officers at the 2024-04-25 meeting.

“The approval, on an advisory basis, of the compensation paid to our named executive officers was approved by the Company’s stockholders based on the following vote: Votes For Votes Against Abstentions Broker Non-Votes 56,633,104.66 1,349,898.04 124,439.00 4,929,820.86”

Lantheus Holdings, Inc. shareholders approved Election of Directors at the 2024-04-25 meeting.

“Nominee Votes For Votes Against Abstentions Broker Non-Votes Brian Markison 55,050,264.70 2,972,256.00 84,921.00 4,929,820.86 Gary Pruden 53,347,262.70 4,674,902.00 85,277.00 4,929,820.86 Dr. James H. Thrall 37,950,899.56 20,017,407.14 139,135.00 4,929,820.86”

Lantheus Holdings, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $354.0 million and $1.3 billion, net income $103.4 million and $326.7 million, EPS $1.47 and $4.65 per fully diluted share. Guidance initiated.

“Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results • Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023 • GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023 • GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023”

Julie McHugh was appointed as Lead Independent Director at Lantheus Holdings, Inc..

“the Board has appointed Julie McHugh as Lead Independent Director of the Board, effective January 23, 2024.”

Brian Markison was appointed as Chief Executive Officer at Lantheus Holdings, Inc..

“The Company has also announced that Brian Markison, the Chairman of the Board, has been appointed Executive Chairman as of January 23, 2024 to serve in that role until the Effective Date and will become the Company’s Chief Executive Officer effective on the Effective Date.”

Brian Markison was appointed as Executive Chairman at Lantheus Holdings, Inc..

“The Company has also announced that Brian Markison, the Chairman of the Board, has been appointed Executive Chairman as of January 23, 2024 to serve in that role until the Effective Date and will become the Company’s Chief Executive Officer effective on the Effective Date.”

Mary Anne Heino was appointed as Chair of the Board at Lantheus Holdings, Inc..

“Ms. Heino will continue to serve as a member of the Board and has been appointed to serve as Chair of the Board as of the Effective Date.”

Mary Anne Heino retired as Chief Executive Officer at Lantheus Holdings, Inc..

“Mary Anne Heino, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), notified the Board on January 18, 2024, of her intention to retire as Chief Executive Officer, effective March 1, 2024”

Lantheus Holdings, Inc. reported fiscal year ended December 31, 2023 results: revenue $1.295 - 1.297 billion.

“Lantheus Reports Preliminary Fiscal Year 2023 Revenue Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion”

Lantheus Holdings, Inc. reported full year 2023 results: revenue $1.255 billion - $1.27 billion, EPS $5.80 - $5.85. Guidance raised.

“The Company updates its guidance for full year 2023 as follows: Guidance Issued November 2, 2023 Previous Guidance Issued August 3, 2023 FY 2023 Revenue $1.255 billion - $1.27 billion $1.245 billion - $1.27 billion FY 2023 Adjusted Fully Diluted EPS $5.80 - $5.85 $5.60 - $5.70”

Lantheus Holdings, Inc. reported the three months ended September 30, 2023 results: revenue $319.9 million, net income $132.0 million, EPS $1.88 per fully diluted share.

“The Company’s worldwide revenue for the third quarter of 2023 totaled $319.9 million, compared with $239.3 million for the third quarter of 2022, representing an increase of 33.7% over the prior year period. The Company’s third quarter 2023 GAAP net income was $132.0 million, or $1.88 per fully diluted share, as compared to GAAP net income of $61.2 million, or $0.86 per fully diluted share for the third quarter of 2022.”

Lantheus Holdings, Inc. reported three and six months ended June 30, 2023 results: revenue $321.7 million, net income $94.1 million, EPS $1.33 per fully diluted share. Guidance raised.

“Lantheus Reports Second Quarter 2023 Financial Results • Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period • GAAP net income of $94.1 million for the second quarter 2023, compared to GAAP net income of $43.1 million in the prior year period • GAAP fully diluted net income per share of $1.33 for the second quarter 2023, compared to GAAP fully diluted net income per share of $0.61 in the prior year period; adjusted fully diluted net income per share of $1.54 for the second quarter 2023, compared to adjusted fully diluted net income per share of $0.89 in the prior year period • Net cash used in operating activities was $32.3 million for the second quarter 2023. Free cash flow was $(43.0) million in the second quarter 2023 • The Company provides third quarter 2023 revenue and adjusted diluted earnings per share guidance; increases full year guidance”

Lantheus Holdings, Inc. amended Lease Amendment with 201 Burlington Road Owner, LLC valued at approximately $83.4 million (effective 2023-05-04).

“On May 4, 2023, Lantheus Medical Imaging, Inc. (the “ Company ”), a wholly owned subsidiary of Lantheus Holdings, Inc. (the “ Registrant ”), entered into a First Amendment To Lease (the “ Lease Amendment ”) with 201 Burlington Road Owner, LLC (the “ Landlord ”), which amends the Company’s existing Office Lease with the Landlord dated February 14, 2022”

Lantheus Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $300.8 million, net income GAAP net loss of $2.8 million, EPS $(0.04) per fully diluted share. Guidance raised.

“The Company’s worldwide revenue for the first quarter of 2023 totaled $300.8 million, compared with $208.9 million for the first quarter of 2022, representing an increase of 44.0% over the prior year period. The Company’s first quarter 2023 GAAP net loss was $2.8 million, or $0.04 per fully diluted share, as compared to GAAP net income of $43.0 million, or $0.61 per fully diluted share for the first quarter of 2022.”

Lantheus Holdings, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-04-27 meeting.

“The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the Company’s stockholders based on the following vote:”

Lantheus Holdings, Inc. shareholders approved Approval of the Lantheus Holdings, Inc. 2023 Employee Stock Purchase Plan at the 2023-04-27 meeting.

“The approval of the Lantheus Holdings, Inc. 2023 Plan was approved by the Company’s stockholders based on the following vote:”

Lantheus Holdings, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to our named executive officers at the 2023-04-27 meeting.

“The approval, on an advisory basis, of the compensation paid to our named executive officers was approved by the Company’s stockholders based on the following vote:”

Lantheus Holdings, Inc. shareholders approved Election of Class II Directors for a three-year term until the 2026 Annual Meeting at the 2023-04-27 meeting.

“Each of the following nominees for Class II director was elected by the Company’s stockholders to serve a three-year term until the 2026 Annual Meeting of Stockholders based on the following vote:”

Paul Blanchfield was appointed as President at Lantheus Holdings, Inc..

“On March 4, 2023, the Compensation Committee of the Board of Directors of Lantheus Holdings, Inc. (the “Company”) appointed Paul Blanchfield as the President of the Company and its subsidiaries, effective March 20, 2023.”

Paul Blanchfield was appointed as President at Lantheus Holdings, Inc..

“On March 4, 2023, the Compensation Committee of the Board of Directors of Lantheus Holdings, Inc. (the “Company”) appointed Paul Blanchfield as the President of the Company and its subsidiaries, effective March 20, 2023.”

Lantheus Holdings, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $263.2 million and $935.1 million, net income GAAP net loss of $119.2 million and GAAP net income of $28.1 million, EPS GAAP fully diluted net loss per share of $1.74 and GAAP fully diluted net income per share of $0.40. Guidance initiated.

“Securities Act of 1933, as amended, or the Exchange Act. --- EX-99.1 (EX-99.1) --- Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results • Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively • GAAP net loss of $119.2”

Lantheus Holdings, Inc.: 修订章程，实施多数投票、更新提前通知条款以符合SEC通用代理规则，并反映特拉华州公司法关于休会通知和股东名单要求的变更 (effective 2022-12-27).

“Effective December 27, 2022, the Board of Directors of Lantheus Holdings, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended and Restated Bylaws”) to (i) implement majority voting in uncontested elections of directors, (ii) include advance notice provisions to address the adoption by the Securities and Exchange Commission of “universal proxy” rules and (iii) reflect amendments to the Delaware General Corporation Law regarding notice of adjourned stockholder meetings and eliminating the requirement of having a stockholder list available at a stockholder meeting, which amendments became effective in August 2022.”

Lantheus Holdings, Inc. incurred convertible notes of $575 million with U.S. Bank Trust Company, National Association at 2.625% maturing December 15, 2027.

“completed its previously announced sale of $575 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027”

Lantheus Holdings, Inc. entered into Indenture with U.S. Bank Trust Company, National Association, as Trustee valued at $575 million (effective 2022-12-08).

“The Notes were issued under an indenture, dated as of December 8, 2022 (the “ Indenture ”), among the Company, Lantheus Medical Imaging, Inc. (the “ Guarantor ”), a wholly owned subsidiary of the Company, as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee.”

Lantheus Holdings, Inc. incurred revolving credit of $350.0 million with Lantheus Medical Imaging, Inc. at The Revolving Loans bear interest, with pricing based from time to time at LMI’s maturing December 2, 2027.

“Under the terms of the New Revolving Facility, the Lenders commit to extend credit to LMI from time to time until December 2, 2027 (the “ Revolving Termination Date ”) consisting of revolving loans (the “ Revolving Loans ”) in an aggregate principal amount not to exceed $350.0 million (the “ Revolving Commitment ”) at any time outstanding, including a $20.0 million sub-facility for the issuance of letters of credit (the “ Letters of Credit ”) and a $10.0 million sub-facility for swingline loans (the “ Swingline Loans ”).”

Lantheus Holdings, Inc. incurred term loan of $100.0 million with Lantheus Medical Imaging, Inc. at The Delayed Draw Term Loan Facility includes a commitment fee equal to 0.20% per maturing The commitment of the Lenders to provide the Delayed Draw Term Loan Facility will be terminated upon funding of any such notes..

“The Credit Agreement establishes (i) a new $100.0 million delayed draw term loan facility (the “ Delayed Draw Term Loan Facility ” and, the loans thereunder, the “ Term Loans ”) and (ii) a new $350.0 million five-year revolving credit facility (the “ New Revolving Facility ” and, together with the Delayed Draw Term Loan Facility, the “ New Facility ”).”

Lantheus Holdings, Inc. terminated Old Facility with The lenders under the Old Facility valued at Repayment in full of approximately $167.6 million of aggregate remaining principal amount plus inter (effective 2022-12-02).

“In connection with the Refinancing, effective as of December 2, 2022, LMI has satisfied and discharged all obligations under, and terminated, the Old Facility, except for obligations that pursuant to the express terms of the Old Facility survive payment of the obligations.”

Lantheus Holdings, Inc. entered into Credit Agreement with Citizens Bank, N.A. (as administrative agent and collateral agent) and the lenders party thereto valued at $100.0 million delayed draw term loan facility and $350.0 million revolving credit facility (effective 2022-12-02).

“On December 2, 2022, Lantheus Holdings, Inc.’s (the “ Company ”) wholly-owned subsidiary Lantheus Medical Imaging, Inc. (“ LMI ”) refinanced its existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “ Old Term Facility ”) and (ii) a $200.0 million five-year revolving credit facility (the “ Old Revolving Facility ” and, together with the Old Term Facility, the “ Old Facility ”), with a new delayed draw term loan facility and a new revolving credit facility (collectively, these transactions are referred to as the “ Refinancing ”). In order to consummate the Refinancing, LMI entered into a Credit Agreement (the “ Credit Agreement ”) by and among Citizens Bank, N.A., as administrative agent (in that capacity, the “ Administrative Agent ”) and collateral agent, each of the lenders from time to time party thereto (the “ Lenders ”) and the Company. The Credit Agreement establishes (i) a new $100.0 million delayed draw term loan facility (the “ Delayed”

Lantheus Holdings, Inc. entered into PNT-2002 License Agreement with POINT Biopharma Global Inc. valued at Upfront cash payment of $250 million; potential milestone payments up to $281 million; sales milesto (effective 2022-11-11).

“On November 11, 2022, Lantheus Two, LLC (“Lantheus Two”), an indirect wholly owned subsidiary of Lantheus Holdings, Inc. (the “Company”), entered into a license and collaboration agreement (the “PNT-2002 License Agreement”) with an affiliate of POINT Biopharma Global Inc. (“POINT”), to co-develop and commercialize PNT-2002, a prostate-specific membrane antigen-targeted radiopharmaceutical therapy for the treatment of metastatic castrate-resistant prostate cancer.”

Lantheus Holdings, Inc. reported the third quarter ended September 30, 2022 results: revenue $239.3 million, net income $61.2 million, EPS $0.86 per fully diluted share. Guidance raised.

“Lantheus Reports Third Quarter 2022 Financial Results • Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period • GAAP net income of $61.2 million for the third quarter 2022, compared to GAAP net loss of $13.4 million in the prior year period • GAAP fully diluted net income per share of $0.86 for the third quarter 2022”

Paul Blanchfield was appointed as Chief Operating Officer at Lantheus Holdings, Inc..

“On June 7, 2022, the Board of Directors of Lantheus Holdings, Inc. (the “Company”) appointed Paul Blanchfield as the Chief Operating Officer of the Company and its subsidiaries, effective June 15, 2022.”